GS — The Goldman Sachs Group, Inc.

The tape is decisively negative: as of 2026-10-14 GS is -10.88% over one month and -23.54% over three months, sitting -3.47% below its 20-day SMA and -8.20% below its 200-day. Even a 'crushing' Q3 beat on 2026-10-13 (sixth consecutive beat, EPS ~30% above consensus) only lifted the stock 0.61% on the day - a classic sign that the market is de-rating the whole capital-markets complex rather than reacting to company-specific news. Analysts are only mildly constructive (consensus 'Hold'; 22 buy vs 30 hold and 3 sell) with an average target of ~$1,118-1,131, so the sell-side is not the source of the negativity - price action is.

The EPS series is the cleanest signal and it is inflecting upward: $5.53 (Q4'23) -> $11.95 (Q4'24) -> $14.12 (Q1'25) -> $12.25 (Q3'25) -> $14.00 (Q4'25) -> $17.55 (Q1'26) -> $20.98 (Q2'26, a record) -> $17.01 (Q3'26). Q3'26 EPS is +38.9% YoY versus $12.25, and the firm has now posted six consecutive beats. Revenue quality is the debate: Q3'26 net revenues rose 23% YoY to $18.68B (second-best quarter in firm history) on a 72% YoY surge in equities (prime financing, portfolio financing, derivatives) and record advisory fees of $1.65B, while FICC was the soft spot at $3.47B (-1% YoY, -24% QoQ). Bottom line: this is a genuine YoY uptrend, not a one-quarter blip, but QoQ is choppy by nature of capital markets, and the FICC weakness is a real mixed signal. Note that FMP's raw revenue line is internally inconsistent (Q1'26 $17.2B vs Q2'26 $38.4B), almost certainly a reporting-basis change - ignore the apparent -43% QoQ revenue move and rely on the EPS series and the brief's net-revenue figure.

As of 2026-10-14 the screen shows a 16.86x trailing P/E and ~13.3x forward P/E (on FMP's next-FY EPS of $67.72), versus a 5-year average P/E of 13.02x - which superficially looks rich. It isn't. FMP's $55.23 TTM EPS does not reconcile with the four most recent reported quarters ($14.00 + $17.55 + $20.98 + $17.01 = $69.54), which puts the true trailing P/E nearer 12.9x - below, not above, the 5-year average. On post-Q3 sell-side numbers (FY26 ~$71.60, FY27 ~$77.00), the stock trades on ~12.5x FY26 and ~11.7x FY27. The 2.54 PEG and $2.53 P/S are distorted by the same revenue-basis artifacts, and the 125.65 P/B is nonsense for a bank actually trading near ~2.2x book ($264.7B market cap / $122.7B equity). Net: fair-to-slightly-cheap against GS's own history for a 13.7% ROE franchise, with a 1.8% dividend yield as a modest floor.

The gap between price and earnings is the entire story. As of 2026-10-14, GS has fallen 23.5% in three months while simultaneously printing a ~30% EPS beat - the market is behaving as if this is peak-cycle earnings and is refusing to pay for the beat, on the theory that record advisory and a 72% equities surge cannot repeat. The counter-argument is that consensus simply has not caught up: FMP's next-FY estimate of $67.72 is BELOW the $69.54 actually earned over the trailing four quarters, and Citizens' post-print numbers ($71.60 FY26 / $77.00 FY27) are higher still. If those hold, the current price is discounting flat-to-down earnings the data do not show. The honest risk is the mirror image - that the market is right and Q3'26 was the high-water mark of this cycle.

As of 2026-10-14: RSI(14) 31.29 (approaching oversold), price -3.47% vs the 20-day SMA (~$930 implied), -10.23% vs the 50-day and -8.20% vs the 200-day - below all three, so this is a confirmed downtrend, not a range. Momentum is back-loaded to the downside: -0.71% 1-week, -10.88% 1-month, -23.54% 3-month, but only -2.06% 6-month, meaning the damage is concentrated in the last quarter rather than a year-long bleed. Entry-timing implication: this is a 'falling knife' profile - oversold enough to bounce, but no moving average reclaimed; the first real evidence of a turn would be a close back above the 20-day on improving volume.

• Interest rates / 'higher for longer': fuels prime brokerage, portfolio financing and restructuring demand, but also pressures wholesale credit - GS booked a $368M provision for credit losses in Q3'26.
• Capital-markets reopening: broad corporate appetite for M&A, IPOs and equity financing produced record $1.65B advisory fees in Q3'26; debt capital markets remain cyclically choppy.
• Financials sector rotation and beta: GS's beta of 1.284 means it amplifies index moves, and the 3-month -23.5% drawdown looks like a sector de-rating rather than company-specific deterioration.
• Regulatory capital (Basel III endgame) and funding costs, which directly affect buyback capacity and return-on-equity math.
• Wealth/asset-management consolidation - integration of recent acquisitions (LCN Capital Partners, NEOS Investments) and the pace of private-equity realizations.

• Q4 2026 earnings on 2027-01-19 - the next test of the six-quarter beat streak and the first look at any FY2027 framing.
• Leadership succession: reports that President/COO John Waldron could succeed David Solomon as early as late 2027-2028, with Solomon potentially moving to executive chairman - a clarity event either way.
• M&A and IPO pipeline execution plus private-equity realizations; successful integration of LCN Capital Partners and NEOS Investments.
• Continued capital return: $4.49B returned to shareholders in Q3'26 and a $5.00 quarterly dividend declared, payable 2026-12-30.
• Fed rate decisions and any broadening of capital-markets activity.

• FICC fragility: down 1% YoY and 24% QoQ to $3.47B in Q3'26 - if the equities/advisory strength normalizes while FICC stays soft, the earnings base is thinner than it looks.
• Credit deterioration if rates stay high: the $368M Q3'26 credit-loss provision is the early warning line.
• Momentum/multiple risk: as of 2026-10-14 the stock is below its 20/50/200-day SMAs with -23.5% three-month momentum; oversold can stay oversold and the downtrend has not broken.
• Earnings-quality noise: a $450M (~$1.00/share) Goldman Sachs Gives contribution hit Q3 GAAP results, and FMP's own data feed contains material inconsistencies (revenue basis change, a broken Q3'26 balance-sheet line showing $2.18B total assets vs $2,127B the prior quarter).
• Regulatory capital changes and political/regulatory scrutiny of large banks, plus succession uncertainty.

This is a strong operating business sitting in a bad tape. Six straight earnings beats, a 38.9% YoY EPS jump in Q3'26, record advisory fees and a 72% equities surge argue the franchise is performing materially better than a 22% drawdown from the 52-week high implies, and at roughly 12-13x trailing/forward earnings GS is at or below its own 5-year average multiple of 13.02x rather than at a premium. The catch is cyclicality and timing: FICC is shrinking, credit provisions are rising, and the technical trend is still down, so a buyer here is purchasing good fundamentals into unresolved momentum. That is a reasonable long-horizon entry, not a tactical all-clear - which is why the lean is Neutral rather than bullish.

Justified forward P/E: I applied a 13.5x multiple - a modest premium to GS's 5-year average P/E of 13.02x, reflecting the structurally improved revenue mix (record advisory, 72% equities growth) and 13.7% ROE - to a next-twelve-month EPS estimate of $75.00, which blends Citizens' post-Q3 FY2026 estimate of $71.60 and FY2027 estimate of $77.00 weighted toward FY2027. That yields $1,012.50, about 13% above the 2026-10-14 price of $897.37 and below the sell-side consensus target of ~$1,118-1,131.